Essential gene identification and drug target prioritization in Leishmania species.

Leishmaniasis is one of the neglected tropical diseases (NTDs), mainly affecting impoverished communities and having varied ranges of pathogenicity according to the diverse spectrum of clinical manifestations. It is endemic in many countries and poses major challenges to healthcare systems in developing countries. Despite the fact that most of the current mono and combination therapies are found to be failures, clear perception of gene essentiality for parasite survival are now desideratum to identify potential biochemical targets through selection. Here we used the metabolic network of L. major, to perform a comprehensive set of in silico deletion mutants and have systematically recognized a clearly defined set of essential proteins by combining several essential criteria. In this paper we summarize the efforts to prioritize potential drug targets up to a five-fold enrichment compared with a random selection.

[1]  G. Church,et al.  Modular epistasis in yeast metabolism , 2005, Nature Genetics.

[2]  Jason A. Papin,et al.  Systems analysis of metabolism in the pathogenic trypanosomatid Leishmania major , 2008, Molecular systems biology.

[3]  C. Pál,et al.  Metabolic network analysis of the causes and evolution of enzyme dispensability in yeast , 2004, Nature.

[4]  Robert P. St.Onge,et al.  Defining genetic interaction , 2008, Proceedings of the National Academy of Sciences.

[5]  A. Cowman,et al.  Functional genomics: identifying drug targets for parasitic diseases. , 2003, Trends in parasitology.

[6]  K. Tyler.  Review of "Leishmania- after the Genome" by Peter J. Myler and Nicolas Fasel , 2008, Parasites & Vectors.

[7]  M. Rockman,et al.  Reverse engineering the genotype–phenotype map with natural genetic variation , 2008, Nature.

[8]  Kenneth J. Kauffman,et al.  Advances in flux balance analysis. , 2003, Current opinion in biotechnology.

[9]  B. Palsson,et al.  The Escherichia coli MG1655 in silico metabolic genotype: its definition, characteristics, and capabilities. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[10]  R. Arni,et al.  Molecular adaptability of nucleoside diphosphate kinase b from trypanosomatid parasites: stability, oligomerization and structural determinants of nucleotide binding. , 2011, Molecular bioSystems.

[11]  Andrea Ilari,et al.  Molecular basis of antimony treatment in leishmaniasis. , 2009, Journal of medicinal chemistry.

[12]  Daniel Segrè,et al.  Epistatic Interaction Maps Relative to Multiple Metabolic Phenotypes , 2011, PLoS genetics.

[13]  J. Hasty,et al.  Reverse engineering gene networks: Integrating genetic perturbations with dynamical modeling , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[14]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[15]  G. Church,et al.  Expression dynamics of a cellular metabolic network , 2005, Molecular systems biology.

[16]  Marsden Pd.  Current concepts in parasitology: leishmaniasis. , 1979 .

[17]  B. Palsson,et al.  Metabolic Flux Balancing: Basic Concepts, Scientific and Practical Use , 1994, Bio/Technology.

[18]  A. Barabasi,et al.  Lethality and centrality in protein networks , 2001, Nature.

[19]  Smita Rai,et al.  Leishmania donovani trypanothione reductase: role of urea and guanidine hydrochloride in modulation of functional and structural properties. , 2009, Biochimica et biophysica acta.

[20]  S. Oliver,et al.  Plasticity of genetic interactions in metabolic networks of yeast , 2007, Proceedings of the National Academy of Sciences.

[21]  Daniel Kuhn,et al.  Combining Global and Local Measures for Structure-Based Druggability Predictions , 2012, J. Chem. Inf. Model..

[22]  M. O. Khan,et al.  Trypanothione Reductase: A Viable Chemotherapeutic Target for Antitrypanosomal and Antileishmanial Drug Design , 2007, Drug target insights.

[23]  Lei Xie,et al.  Structure-based systems biology for analyzing off-target binding. , 2011, Current opinion in structural biology.

[24]  Antoine M. van Oijen,et al.  Real-time single-molecule observation of rolling-circle DNA replication , 2009, Nucleic acids research.

[25]  U. Sauer,et al.  Large-scale 13C-flux analysis reveals mechanistic principles of metabolic network robustness to null mutations in yeast , 2005, Genome Biology.

[26]  A. Fairlamb,et al.  Trypanothione Reductase High-Throughput Screening Campaign Identifies Novel Classes of Inhibitors with Antiparasitic Activity , 2009, Antimicrobial Agents and Chemotherapy.

[27]  A. Fairlamb,et al.  Drug Resistance in Leishmaniasis , 2006, Clinical Microbiology Reviews.

[28]  David S. Wishart,et al.  Development of a Novel Virtual Screening Cascade Protocol to Identify Potential Trypanothione Reductase Inhibitors , 2009, Journal of medicinal chemistry.

[29]  A. Tielens,et al.  Adaptations in the lipid metabolism of the protozoan parasite Trypanosoma brucei , 2006, FEBS letters.

[30]  Nisha Singh,et al.  Leishmaniasis: current status of available drugs and new potential drug targets. , 2012, Asian Pacific journal of tropical medicine.

[31]  Yang Zhang,et al.  BioLiP: a semi-manually curated database for biologically relevant ligand–protein interactions , 2012, Nucleic Acids Res..

[32]  Andreas Wagner,et al.  Estimating coarse gene network structure from large-scale gene perturbation data. , 2002, Genome research.

[33]  A. Tielens,et al.  Surprising variety in energy metabolism within Trypanosomatidae. , 2009, Trends in parasitology.

[34]  L. Guarente.  Synthetic enhancement in gene interaction: a genetic tool come of age. , 1993, Trends in genetics : TIG.

[35]  A. Barabasi,et al.  Network biology: understanding the cell's functional organization , 2004, Nature Reviews Genetics.

[36]  M. Ouellette,et al.  Modulation of gene expression in Leishmania drug resistant mutants as determined by targeted DNA microarrays. , 2003, Nucleic acids research.

[37]  H. Kitano.  A robustness-based approach to systems-oriented drug design , 2007, Nature Reviews Drug Discovery.

[38]  A. Ilari,et al.  Polyamine metabolism in Leishmania: from arginine to trypanothione , 2011, Amino Acids.

[39]  S. Sundar.  Drug resistance in Indian visceral leishmaniasis , 2001, Tropical medicine & international health : TM & IH.

[40]  Kellen L. Olszewski,et al.  Reconstruction and flux-balance analysis of the Plasmodium falciparum metabolic network , 2010, Molecular systems biology.

[41]  B. Palsson,et al.  Properties of metabolic networks: structure versus function. , 2005, Biophysical journal.

[42]  Frederick P Roth,et al.  Q&A: Epistasis , 2009, Journal of biology.

[43]  Bernhard O. Palsson,et al.  Identification of Genome-Scale Metabolic Network Models Using Experimentally Measured Flux Profiles , 2006, PLoS Comput. Biol..

[44]  Daniel Segrè,et al.  From annotated genomes to metabolic flux models and kinetic parameter fitting. , 2003, Omics : a journal of integrative biology.

[45]  P. Phillips.  Epistasis — the essential role of gene interactions in the structure and evolution of genetic systems , 2008, Nature Reviews Genetics.

[46]  Michael P. Barrett,et al.  MetExplore: a web server to link metabolomic experiments and genome-scale metabolic networks , 2010, Nucleic Acids Res..

[47]  D. Fell,et al.  Fat synthesis in adipose tissue. An examination of stoichiometric constraints. , 1986, The Biochemical journal.

[48]  M. Gramiccia,et al.  A gold-containing drug against parasitic polyamine metabolism: the X-ray structure of trypanothione reductase from Leishmania infantum in complex with auranofin reveals a dual mechanism of enzyme inhibition , 2011, Amino Acids.

[49]  B. Palsson,et al.  Metabolic Capabilities of Escherichia coli II. Optimal Growth Patterns , 1993 .

[50]  G. Church,et al.  Analysis of optimality in natural and perturbed metabolic networks , 2002 .

[51]  J. Janin,et al.  Three-Dimensional Structure of Nucleoside Diphosphate Kinase , 2000, Journal of bioenergetics and biomembranes.

[52]  Adam R Renslo,et al.  Drug discovery and development for neglected parasitic diseases , 2006, Nature chemical biology.

[53]  S. Croft.  Monitoring drug resistance in leishmaniasis , 2001, Tropical medicine & international health : TM & IH.

[54]  A. Casini,et al.  New uses for old drugs. Auranofin, a clinically established antiarthritic metallodrug, exhibits potent antimalarial effects in vitro: Mechanistic and pharmacological implications , 2008, FEBS letters.

[55]  E. Ruppin,et al.  Regulatory on/off minimization of metabolic flux changes after genetic perturbations. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[56]  Kiran Raosaheb Patil,et al.  Impact of Stoichiometry Representation on Simulation of Genotype-Phenotype Relationships in Metabolic Networks , 2012, PLoS Comput. Biol..